A Comparison of the Conformability of Everolimus-Eluting Bioresorbable Vascular Scaffolds to Metal Platform Coronary Stents
نویسندگان
چکیده
منابع مشابه
Comparison of Everolimus- and Biolimus-Eluting Coronary Stents With€Everolimus-Eluting Bioresorbable Vascular Scaffolds
Fro ini Du an res da Bio (CR Lis Yo Ma BACKGROUND The first CE-approved bioresorbable vascular scaffold (BVS) is effective at treating simple lesions and stable coronary artery disease, but it has yet to be assessed versus the best-in-class drug-eluting stents (DES). OBJECTIVES This study sought to compare the performance of a BVS with that of everolimus-eluting stents (EES) and biolimus-elutin...
متن کاملIntraindividual Comparison of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Drug-Eluting Metallic Stents.
BACKGROUND The performance of everolimus-eluting bioresorbable vascular scaffold (BVS) versus drug-eluting metallic stent (DES) in the same individual receiving multilesion percutaneous coronary intervention (PCI) remains poorly studied. This report investigates the intraindividual performance of BVS and DES in patients receiving multilesion PCI and follow-up angiography. METHODS AND RESULTS ...
متن کاملLong-Term Efficacy and Safety of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents
Second-generation metallic drug-eluting stents (DES) have been widely recommended for percutaneous coronary intervention. One of the main drawbacks of these devices is the risk of late adverse events (ie, beyond 1 year), particularly repeat revascularization, which are partly related to the persistence of the metallic stents in the coronary artery wall. In this context, the bioresorbable vascul...
متن کاملComparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds: Two-year clinical outcomes of the EVERBIO II trial.
BACKGROUND Data from randomized controlled trials have shown that the ABSORB BVS is non-inferior to Cobalt Chromium everolimus-eluting stents at 2years. METHODS & RESULTS The EVERBIO II trial (Comparison of Everolimus- and Biolimus-Eluting Coronary Stents with Everolimus-Eluting Bioresorbable Vascular Scaffold) is a single-center, assessor-blind, randomized controlled trial enrolling 240 pati...
متن کاملEverolimus-eluting coronary stents
Bare metal stents enabled a reduction in the risk of early procedural complications and restenosis in comparison with balloon angioplasty alone, but introduced a new and device-specific iatrogenic condition, ie, in-stent restenosis due to increased neointimal hyperplasia. Sirolimus- and paclitaxel-eluting stents reduce restenosis and the need for new revascularizations in comparison with bare m...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: JACC: Cardiovascular Interventions
سال: 2010
ISSN: 1936-8798
DOI: 10.1016/j.jcin.2010.07.016